4570 — Immuno-Biological Laboratories Co Balance Sheet
0.000.00%
- ¥5bn
- ¥4bn
- ¥970m
- 67
- 26
- 57
- 50
Annual balance sheet for Immuno-Biological Laboratories Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 604 | 508 | 614 | 734 | 826 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 199 | 174 | 216 | 190 | 232 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,125 | 1,130 | 1,165 | 1,262 | 1,390 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 127 | 120 | 119 | 136 | 191 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 1,838 | 1,705 | 1,434 | 1,619 | 1,845 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 145 | 228 | 252 | 258 | 281 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 209 | 337 | 356 | 353 | 331 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 1,629 | 1,368 | 1,079 | 1,265 | 1,514 |
Total Liabilities & Shareholders' Equity | 1,838 | 1,705 | 1,434 | 1,619 | 1,845 |
Total Common Shares Outstanding |